NCT04682431: A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: TREM
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients with tumors that express TREM1 will also be eligible for the dose expansion phase of the study
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details; Patients who are eligible and have not progressed on molecularly targeted therapy (e.g. drugs targeting EGFR, HER2, etc)

Comments are closed.

Up ↑